Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential
Neurocrine Biosciences (NASDAQ:NBIX) has been identified as a strong candidate for an "Affordable Growth" strategy due to its robust fundamentals, including high growth, profitability, and health ratings, coupled with a reasonable valuation. The company shows significant past and projected earnings and revenue growth, along with a healthy balance sheet and strong profit margins. Its valuation, when compared to industry peers and future growth prospects, suggests it is currently undervalued, making it an attractive option for growth-oriented value investors.
Director at Neurocrine (NASDAQ: NBIX) converts 3,318 RSUs to stock
Neurocrine Biosciences director Stephen A. Sherwin exercised 3,318 Restricted Stock Units (RSUs) into common shares on May 21, 2026, at an exercise price of $0.00 per share. This RSU award, granted on May 21, 2025, is now fully vested, and Sherwin directly holds 15,860 shares of Neurocrine common stock following the transaction. The Form 4 filing details this compensation-related conversion, emphasizing it was not an open-market purchase or sale.
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk exercised 1,659 restricted stock units (RSUs) into common shares on May 21, 2026. This transaction increased Norwalk's direct holdings to 4,088 shares of Common Stock. The RSU award was granted on May 21, 2025, and was fully vested, representing a routine compensation settlement rather than a new market purchase or sale.
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity
Neurocrine Biosciences director Kevin Charles Gorman reported exercising 205,088 Non-Qualified Stock Options and simultaneously selling 245,088 common shares. The sales were executed under a pre-arranged Rule 10b5-1 trading plan at a weighted average price of $154.3318 per share. Following these transactions, Gorman maintains a substantial holding of 511,293 common shares through the Gorman and Blais Family Trust.
Neurocrine Biosciences director Kevin Gorman sells $37.8m in stock
Kevin Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold approximately $37.8 million worth of common stock on May 19, 2026, through a Rule 10b5-1 trading plan which also involved exercising stock options. Prior to the sale, Gorman acquired 205,088 shares by exercising non-qualified stock options, and he now directly holds 511,293 shares. This comes amidst strong financial results for Neurocrine Biosciences, including exceeding Q1 2026 earnings expectations and completing the acquisition of Soleno Therapeutics Inc.
Neurocrine Biosciences (NBIX) Valuation Check As New INGREZZA Real World Data Draws Fresh Attention
Neurocrine Biosciences (NBIX) is drawing attention after new real-world data for its drug INGREZZA highlighted improvements in patients with mild tardive dyskinesia. Despite recent share price gains and strong earnings, the article explores whether the current valuation of US$154.67 still offers upside, with one narrative suggesting it is 17% undervalued at a fair value of US$186.45. Investors are advised to consider potential pricing pressures and review underlying data to form their own investment view.
Neurocrine Biosciences Hits New Highs On Earnings Surge
Neurocrine Biosciences (NBIX) shares recently hit an all-time high of 162.39 following a report of quadruple-digit earnings growth. This performance is particularly noteworthy among biotech stocks, where profitability can be challenging to achieve despite medical advancements. The surge in stock price occurred after the company's first-quarter earnings report.
New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX)
Neurocrine Biosciences recently reported strong Q1 2026 revenue and net income, alongside new CRENESSITY dosing algorithms and INGREZZA data. These developments are expected to deepen clinical confidence in their therapies and support endocrinology growth, although the company still faces risks from portfolio concentration and potential payer pressures. Analysts project significant revenue and earnings growth by 2029, suggesting a potential upside to its current stock price.
Morgan Stanley lists Rule 144 sale of NBIX-linked shares | NBIX SEC Filing - Form 144
Morgan Stanley Smith Barney LLC has filed a Rule 144 notice to sell securities linked to NBIX stock. The filing includes 40,000 previously vested Restricted Stock Units (RSUs)/Performance Stock Units (PSUs) and 205,088 shares from a stock option exercise on May 19, 2026. These transactions indicate a disposition of company shares by the entity.
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences announced new real-world data showing that even mild tardive dyskinesia (TD) significantly impairs daily functioning, and treatment with INGREZZA® (valbenazine) capsules leads to substantial improvements. A clinician survey indicated that 90% of patients with mild TD experienced emotional, social, or physical impairment, with 96% showing improved uncontrolled movements after INGREZZA initiation, and functional status improvements across various daily activities. These findings, presented at the American Psychiatric Association 2026 Annual Meeting, reinforce INGREZZA's benefits for individuals with TD, including those with mild symptoms.
Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules
Neurocrine Biosciences announced new data from the KINECT-HD study and real-world evidence from the RE-KINECT study, showing that Ingrezza (valbenazine) capsules are associated with functional improvements in patients with tardive dyskinesia (TD). The findings, presented at the American Psychiatric Association (APA) Annual Meeting, support Ingrezza's efficacy in treating motor symptoms and improving functional outcomes for TD patients.
Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal
Neurocrine Biosciences announced new data from a clinician survey presented at APA 2026, highlighting the positive functional impact of its drug INGREZZA on patients with mild tardive dyskinesia. Concurrently, the company confirmed the completion of its $2.9 billion acquisition of Soleno Therapeutics, adding VYKAT XR, a treatment for Prader-Willi syndrome, to its commercial portfolio. The acquisition expands Neurocrine's rare disease offerings, while the INGREZZA findings reinforce its standing in movement disorder treatments.
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock
Richard F. Pops, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold 15,000 shares for $2.36 million and simultaneously acquired 15,000 shares by exercising stock options on May 15, 2026. This comes as NBIX trades near its 52-week high and has reported strong Q1 2026 earnings, an acquisition of Soleno Therapeutics Inc., and positive data for its drug INGREZZA.
Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan
Richard F. Pops, a director at Neurocrine Biosciences (NBIX), exercised 15,000 Non-Qualified Stock Options and subsequently sold 15,000 common shares in open-market transactions. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, took place at a weighted average price of $157.6507 per share. Following these transactions, Pops directly holds 34,480 shares of Neurocrine common stock.
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq
Soleno Therapeutics has completed its merger with Neurocrine Biosciences, becoming a wholly owned subsidiary of Neurocrine. The transaction involved a tender offer for $53.00 per share and has led to Soleno delisting its shares from the Nasdaq Capital Market and planning to deregister with the SEC. Following the acquisition, Soleno also withdrew its European marketing authorization application for VIOKAT.
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences announced new real-world data showing that even mild tardive dyskinesia (TD) significantly impairs patients' daily functioning. The data, from a clinician survey, also demonstrated that treatment with INGREZZA (valbenazine) capsules led to improvements in uncontrolled movements and functional status in 96% of mild TD patients, with most showing improvement within four weeks. These findings support INGREZZA's benefits for TD patients, including those with mild symptoms, aligning with American Psychiatric Association guidelines.
Survey: 'mild' movement disorder disrupts life, most improve on INGREZZA
Neurocrine Biosciences presented real-world data showing that mild tardive dyskinesia (TD) significantly impairs daily functioning, but treatment with INGREZZA led to substantial improvements. A clinician survey of patients with mild TD revealed that 90% experienced functional impairment before treatment, while 96% showed improved uncontrolled movements after starting INGREZZA, with 86% improving within four weeks. The findings highlight INGREZZA's potential to enhance functional status, independence, and work/school participation for individuals with even mild TD.
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B
Neurocrine Biosciences has completed its $2.9 billion acquisition of Soleno Therapeutics, enhancing its portfolio in endocrinology and rare diseases. This acquisition integrates VYKAT XR, an approved treatment for hyperphagia in Prader-Willi syndrome, into Neurocrine's commercial offerings. The move aims to expand access to life-changing treatments for patients with significant unmet needs.
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics
Neurocrine Biosciences has completed its $2.9 billion acquisition of Soleno Therapeutics, a move expected to significantly bolster its neuroscience pipeline. The acquisition brings Soleno's lead investigational drug, D-PLEX101, for Prader-Willi Syndrome into Neurocrine's portfolio, with potential for further label expansion. This strategic transaction aims to enhance Neurocrine's growth trajectory and address a high unmet medical need.
Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics
Neurocrine Biosciences has announced the completion of its acquisition of Soleno Therapeutics. This brief announcement confirms the successful conclusion of the transaction between the two companies.
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq
Soleno Therapeutics has completed its merger with Neurocrine Biosciences, becoming a wholly-owned subsidiary of Neurocrine after a tender offer acquired approximately 88.9% of Soleno's shares for $53.00 each. Following the merger, Soleno's shares have been delisted from Nasdaq, and leadership changes have been implemented. The company also recently withdrew its European marketing application for VIOKAT and has been the subject of analyst rating adjustments.
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio
Neurocrine Biosciences Inc. has completed its $2.9 billion acquisition of Soleno Therapeutics Inc., gaining VYKAT XR, an FDA-approved treatment for hyperphagia associated with Prader-Willi syndrome. This acquisition expands Neurocrine's rare disease portfolio and commercial footprint, diversifying its business beyond neuroscience. The deal strengthens Neurocrine's position in specialty diseases requiring long-term patient management and infrastructure, addressing a significant unmet medical need.
Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition
Neurocrine Biosciences has completed its all-cash acquisition of Soleno Therapeutics for approximately $2.9 billion, or $53.00 per Soleno share. This acquisition adds VYKAT XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's commercial portfolio. To finance this and ensure flexibility, Neurocrine also entered into a new $1.0 billion senior secured revolving credit facility, initially borrowing $600.0 million.
Neurocrine Biosciences stock (US64125C1099): momentum after strong run in May and growing neuroscien
Neurocrine Biosciences (NBIX) stock has shown strong momentum in May 2026, performing well on Nasdaq and trading near the upper end of its 52-week range. The mid-cap biopharmaceutical company focuses on neurological and endocrine disorders, expanding its pipeline beyond movement disorders to include pediatric epilepsy and endocrine indications. Investors are closely monitoring the company's established neurology franchise, late-stage endocrine pipeline, and recent clinical milestones.
[144] NEUROCRINE BIOSCIENCES INC SEC Filing
This SEC filing (Form 144) for Neurocrine Biosciences Inc. (NBIX) reports a proposed sale of 15,000 shares of common stock with an aggregate market value of $2,385,750, acquired via exercise of stock options on May 15, 2026. The sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ. The document provides detailed information about the filer, issuer, and the securities transaction.
Neurocrine (NBIX) director pre-plans sale of 3,810 shares via 10b5-1 plan
Neurocrine Biosciences Inc. director Leslie V. Norwalk sold 3,810 shares of common stock at a weighted average price of $155.0134 per share through an open-market transaction. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, adopted on September 15, 2025. Following the transaction, Norwalk now directly holds 2,429 shares of NBIX common stock.
Neurocrine Biosciences director Norwalk sells $590,601 in stock
Leslie V Norwalk, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold 3,810 shares totaling $590,601 on May 12, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred while NBIX stock was near its 52-week high, with Ms. Norwalk retaining 2,429 shares. The sale follows a strong Q1 2026 performance where the company exceeded earnings and revenue expectations.
Neurocrine Biosciences stock (US64125C1099): Recent clinical trial advancements and market position
Neurocrine Biosciences (NBIX) is advancing its pipeline with new data on rare disease treatments, particularly for congenital adrenal hyperplasia and tardive dyskinesia, positioning itself as a key player in neurology. The company's lead product, INGREZZA, continues to be a primary revenue driver, while pipeline candidates like crinecerfont for CAH are nearing regulatory submission. These developments are closely watched by US investors due to Neurocrine's Nasdaq listing and focus on high-value rare disease markets.
Neurocrine Biosciences (NBIX) Valuation After Strong Q1 2026 Results And New CRENESSITY And Obesity Pipeline Updates
Neurocrine Biosciences (NBIX) is drawing attention after a strong Q1 2026 performance with increased revenue and net income, alongside positive CRENESSITY clinical data and new guidance on glucocorticoid dose reduction. The company's stock has seen significant momentum, with a 30-day return of 20.88% and a one-year return of 33.31%, yet it is still considered 16.4% undervalued with a narrative fair value of $186.45. This valuation is driven by the rapid adoption and blockbuster potential of CRENESSITY, though potential risks like pricing headwinds for INGREZZA and concentration risk in late-stage programs are noted.
Neurocrine Biosciences (NBIX) Valuation After Strong Q1 2026 Results And New CRENESSITY And Obesity Pipeline Updates
Neurocrine Biosciences (NBIX) is seeing increased attention following strong Q1 2026 results, positive CRENESSITY clinical data, and updates on its obesity pipeline. The stock has shown strong momentum, with significant share price and shareholder returns over the last year. Despite a perceived intrinsic discount, the article explores whether the market is already factoring in anticipated growth driven by potential blockbuster status for CRENESSITY and sustained revenue increases.
Number of shareholders of Neurocrine Biosciences, Inc. – MIL:1NBIX
This article provides details on the number of shareholders for Neurocrine Biosciences, Inc. (MIL:1NBIX) as part of its financial overview on TradingView. It indicates that the company is listed on Euronext Milan and includes various market data and reference data disclaimers. The page appears to be a financial data hub rather than a news article about shareholder numbers.
Neurocrine Biosciences (NBIX) Valuation After Strong Q1 2026 Results And New CRENESSITY And Obesity Pipeline Updates
Neurocrine Biosciences (NBIX) reported strong Q1 2026 results with double-digit revenue and net income growth, alongside positive CRENESSITY clinical data and new guidance. The stock has seen significant momentum, with a 30-day return of 20.88% and a one-year return of 33.31%. Despite this, Simply Wall St's narrative model indicates the stock is 16.4% undervalued, with a fair value of $186.45 compared to its last closing price of $155.80, driven by the potential blockbuster status of CRENESSITY.
[144] NEUROCRINE BIOSCIENCES INC SEC Filing
This article reports on a Form 144 SEC filing by Neurocrine Biosciences Inc. (NBIX). The filing details a proposed sale of 6,310 shares of common stock acquired through a stock option exercise, with an aggregate market value of $1,028,050.00. The sale is planned for May 12, 2026, through The Charles Schwab Corporation on the NASDAQ.
Neurocrine Biosciences stock (US64125C1099): Q1 2026 earnings beat with $815M revenue
Neurocrine Biosciences reported a strong Q1 2026, with revenue of $814.5 million and net income of $197.9 million, surpassing analyst expectations. The company also provided positive updates on its neuroscience pipeline, including CRENESSITY and a new obesity candidate. This performance, coupled with a robust pipeline, positions the biopharmaceutical company favorably in the market, with its stock closing at $150.59 on May 11, 2026, and a year-to-date increase of 6.2%.
Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data Release - Has The Bull Case Changed?
Neurocrine Biosciences reported strong first-quarter results with $814.5 million in revenue and $197.9 million in net income, alongside significant updates for its CRENESSITY therapy and a new obesity candidate. The new data for CRENESSITY, including expert dosing algorithms and two-year pediatric data, suggests its growing integration in congenital adrenal hyperplasia care, which could help reduce the company's reliance on INGREZZA. While the company's forecast projects significant revenue and earnings growth, investors should consider the evolving reimbursement landscape and potential payer scrutiny as crucial factors.
Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data Release - Has The Bull Case Changed?
Neurocrine Biosciences (NBIX) reported strong Q1 2026 results with revenue of US$814.5 million and net income of US$197.9 million, along with positive clinical updates for CRENESSITY and a new obesity candidate. The new CRENESSITY data, including expert dosing algorithms and two-year pediatric results, suggest increasing medical integration for the therapy. This performance reinforces the company's investment narrative, which relies on the growth of INGREZZA and CRENESSITY, though investors should consider potential pricing pressures and reimbursement risks.
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $180
RBC Capital has reiterated its Buy rating on Neurocrine Biosciences (NBIX.US), maintaining a target price of $180. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation. Investors may view this as a sign of confidence in Neurocrine Biosciences' future prospects.
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next
Neurocrine Biosciences (NASDAQ:NBIX) exceeded Q1 revenue and EPS forecasts, with revenue at US$815m (6.4% above estimates) and EPS at US$1.91 (61% ahead of expectations). Following these strong results, analysts have become more bullish on the company's earnings per share estimates for 2026, though the consensus price target remained unchanged at US$191. The company is projected to see significant revenue growth, outpacing its industry peers.
Neurocrine Biosciences, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) recently surpassed analyst earnings per share and revenue estimates for the first quarter, posting a statutory profit of US$1.13 per share and a 7.5% revenue surprise. Despite this, analysts have slightly decreased their revenue forecasts for the current year, though maintaining a strong average price target of US$165. Share price movements will likely be influenced more by changes in earnings expectations than by the minor revenue adjustments.
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next
Neurocrine Biosciences recently reported strong Q1 results, with revenue of US$815m and EPS of US$1.91, significantly beating analyst expectations. Following these results, analysts have updated their models, now forecasting US$3.76b in revenue for 2026 and an increased EPS forecast of US$5.01, indicating a more bullish outlook for the company's earnings potential and faster-than-industry revenue growth despite an unchanged consensus price target.
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $185
J.P. Morgan has reiterated its Buy rating for Neurocrine Biosciences (NBIX.US) and increased the target price for the company's stock to $185. This suggests a continued positive outlook from the financial institution regarding Neurocrine Biosciences' performance and future prospects.
Earnings Beat: Neurocrine Biosciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Neurocrine Biosciences, Inc. (NBIX) recently reported strong quarterly results, with revenues exceeding expectations and statutory profit significantly higher than analysts forecasted. Following these results, analysts have updated their models, becoming more bullish on the company's earnings per share for 2026, though the consensus price target remains unchanged at US$191. The company's future revenue growth is also expected to accelerate, outpacing the wider industry.
Neurocrine Biosciences Stock Rockets 17% With 9-Day Winning Streak
Neurocrine Biosciences stock has seen a significant surge, rocketing 17% and achieving a 9-day winning streak. The article, while brief, highlights this strong recent performance for the company's shares.
Neurocrine Biosciences Stock 8-Day Winning Spree: Stock Climbs 15%
The article reports that Neurocrine Biosciences (NBIX) stock has experienced an 8-day winning streak, resulting in a 15% increase in its stock price. The content provided is minimal and appears to be a stub or an incomplete article from a financial data platform.
Research Alert: CFRA Keeps Hold Rating On Shares Of Neurocrine Biosciences Inc.
CFRA has maintained its Hold rating on Neurocrine Biosciences Inc. shares. This rating indicates a neutral outlook on the company's stock performance.
Neurocrine Biosciences (NBIX) Earnings Surge Challenges Cautious Narratives On Margin Durability
Neurocrine Biosciences (NBIX) reported strong Q1 2026 earnings with a significant surge in both revenue and EPS, challenging cautious views on its margin durability. The company's earnings growth of 118.6% outpaced revenue growth, indicating improved profit margins. While valuation metrics present a mixed picture compared to analyst targets and the broader biotech industry, the strong financial performance provides concrete backing for bullish arguments regarding its product portfolio and pipeline.
Big Q1 2026 jump as Neurocrine (NASDAQ: NBIX) inks $2.9B Soleno buy
Neurocrine Biosciences reported strong first-quarter 2026 results with total revenues of $814.5 million, up 42% year-over-year, driven by its neurology and endocrine drugs, INGREZZA and CRENESSITY. The company also announced a definitive agreement to acquire Soleno Therapeutics for an equity value of $2.9 billion, adding VYKAT XR for Prader-Willi syndrome and reaffirming its 2026 INGREZZA net sales guidance. With a robust cash position and ongoing clinical developments, Neurocrine is focused on expanding its portfolio and market presence.
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Neurocrine Biosciences announced strong first-quarter 2026 financial results, with total net product sales reaching $811.0 million, a 44% increase year-over-year. The company also reported a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, aiming to expand its portfolio with VYKAT™ XR for Prader-Willi Syndrome. Neurocrine reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 - $2.8 billion, highlighting continued growth across its commercial and pipeline initiatives.
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences has announced the publication of expert recommendations for reducing glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) who are receiving CRENESSITY® (crinecerfont). These new algorithms, published in The Journal of Clinical Endocrinology & Metabolism, provide practical guidance for healthcare providers, tailored for both pediatric and adult patients, aiming to enable more physiologic GC dosing while controlling androgen production. The recommendations emphasize gradual, clinically supervised dose reductions and monitoring of biomarkers, recognizing that GC reduction is not a universal goal for all patients.
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences announced the publication of expert recommendations for reducing glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) treated with CRENESSITY. These recommendations, published in The Journal of Clinical Endocrinology & Metabolism, provide structured algorithms for both pediatric and adult patients. CRENESSITY helps lower excessive androgen production, allowing for more physiologic GC dosing and reducing risks associated with long-term supraphysiologic GC exposure.
